SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board
August 22 2024 - 8:12AM
SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a
specialty clinical-stage pharmaceutical company focusing on the
development of therapies to treat disorders of the central nervous
system, announced that MitoCareX Bio Ltd. ("MitoCareX"), the
Company’s venture with Dr. Alon Silberman that focuses on drug
discovery and development of therapeutics for cancer and other
life-threatening conditions by targeting the mitochondrial SLC25
protein family, has appointed Professor Nir Peled as a member of
its scientific advisory board.
Professor Peled is a distinguished expert in thoracic oncology,
holding board certifications in internal medicine, pulmonology, and
medical oncology. His extensive contributions to the field are
well-recognized, having served as a board member of the
International Association for the Study of Lung Cancer (IASLC) and
currently the chair of the Global Multidisciplinary Practice
Standards Committee (GMPSC), as well as past Chair of the IASLC's
Screening & Early Detection Committee. Additionally, he
recently concluded his term as the Chair of the Thoracic Cancer
Assembly of the European Thoracic Society.
With a research portfolio that spans translational and clinical
aspects of lung cancer, Professor Peled's work is focused on
personalized targeted therapy, immunotherapy, cancer evolution,
biomarker development, and the early detection of lung cancer. His
scholarly output includes over 250 peer-reviewed publications,
encompassing key guidelines on the early diagnosis of lung cancer,
biomarker development, and the treatment of advanced disease.
Professor Peled also serves on the editorial boards of numerous
prestigious journals, including the Journal of Thoracic Oncology,
further contributing to the advancement of lung cancer research and
treatment.
Dr. Alon Silberman, Chief Executive Officer of MitoCareX,
comment “We are proud to welcome Professor Nir Peled, a Key Opinion
Leader oncologist with an impressive track record, to our team. We
believe that his professional contributions will be significant as
we continue to advance our company's cutting-edge technologies for
discovering and developing innovative cancer treatments.”
As previously announced by the Company on July 22, 2024,
MitoCareX validated the significant involvement of its target SLC25
carrier protein, using Non-Small Cell Lung Cancer (NSCLC) cells
with diverse genetic backgrounds. MitoCareX demonstrated the
discovery by utilizing genetic manipulations and 3D spheroid
systems, mimicking the main features of human solid tumors.
Previously, MitoCareX had virtually screened millions of small
molecules by using its computationally advanced drug discovery
platform, which includes its proprietary MITOLINE™ algorithm.
Following the successful virtual screening campaign, MitoCareX
identified several small molecules that could potentially be used
for anti-cancer treatments.
About SciSparc Ltd.
(Nasdaq: SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical
company led by an experienced team of senior executives and
scientists. SciSparc’s focus is on creating and enhancing a
portfolio of technologies and assets based on cannabinoid
pharmaceuticals. With this focus, the Company is currently engaged
in the following drug development programs based on THC and/or
non-psychoactive CBD: SCI-110 for the treatment of Tourette
Syndrome, for the treatment of Alzheimer's disease and agitation;
SCI-160 for the treatment of pain; and SCI-210 for the treatment of
ASD and status epilepticus. The Company also owns a controlling
interest in a subsidiary whose business focuses on the sale of hemp
seeds’ oil-based products on Amazon Marketplace.
Forward-Looking Statements:
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other federal
securities laws. For example, SciSparc is using forward-looking
statements when it discusses MitoCareX’s belief that Professor
Peled’s professional contributions will be significant. Historical
results of scientific research and clinical and preclinical trials
do not guarantee that the conclusions of future research or trials
will suggest identical or even similar conclusions. Because such
statements deal with future events and are based on SciSparc's
current expectations, they are subject to various risks and
uncertainties and actual results, performance or achievements of
SciSparc could differ materially from those described in or implied
by the statements in this press release. The forward-looking
statements contained or implied in this press release are subject
to other risks and uncertainties, including those discussed under
the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F
filed with the SEC on April 1, 2024, and in subsequent filings
with the U.S. Securities and Exchange Commission. Except as
otherwise required by law, SciSparc disclaims any intention or
obligation to update or revise any forward-looking statements,
which speak only as of the date they were made, whether as a result
of new information, future events or circumstances or
otherwise.
Investor Contact:IR@scisparc.comTel:
+972-3-6167055
SciSparc (NASDAQ:SPRC)
Historical Stock Chart
From Sep 2024 to Oct 2024
SciSparc (NASDAQ:SPRC)
Historical Stock Chart
From Oct 2023 to Oct 2024